Abstract:Objective Crohn's disease (CD) has a variety of clinical manifestations and treatment options. By reviewing the clinical manifestations and treatment options, this study aims to analyze how to rationally select treatment according to the manifestations of CD patients. Methods Patients diagnosed as CD in RenJi Hospital from 2005 to 2014 were divided into two groups based on year of diagnosis: 2005 to 2009 and 2010 to 2014. Medical information was recorded. Results There was no significant difference in clinical manifestations between the two groups. Operation rate during 2010 to 2014 was significantly lower than that during 2005 to 2009 (P?0.05). The operation rate was low in the patients with perianal diseases, while that was high in the patients with penetrating complication. The number of patients who received medicines at the time of diagnosis was significantly increased during 2010 to 2014 when compared with that during 2005 to 2009 (P?0.05). Use of 5-aminosalicylic acid was decreased during 2010 to 2014 when compared with that during 2005 to 2009 (P?0.05), especially in the patients with colonic involvement, non-stricturing and non-penetrating and stricturing behavior. Use of immunosuppressors was increased significantly during 2010 to 2014 when compared with that during 2005 to 2009 (P?0.05), especially in patients aging from 17 to 40 years old, with colonic involvement and stricturing behavior. Use of infliximab was increased significantly during 2010 to 2014 when compared with that during 2005 to 2009 (P?0.05), especially in the patients of ≤ 16 years old, non-stricturing and non-penetrating behavior and had perianal disease. Conclusions Patients without complications most likely adopt the "step-up" strategy, while the "top-down" strategy with infliximab is used in patients of ≤ 16 years old, or with perianal disease. The surgical rate is reduced in patients with complications due to increased application of immunosuppressive therapy. The accelerated "step-up" strategy is rational if conditions are not allowed. In summary, different treatment options should be used according to the different manifestations.